Common Stock, par value $.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 6, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for its third quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
BIOAFFINITY TECHNOLOGIES, INC. · 8-K · Filed 2026-11-06
Tradeable Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
November 6, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release that included
financial information for its third quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
The
information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
Filed exhibits (1)
Exhibit 99.1 News Release bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date Company advances precision medicine pipeline with new asthma and COPD research, collaboration with Pictor and continued development of topical skin cancer therapeutics SAN ANTONIO, Texas - November 6, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today reported financial results and business highlights for the third quarter (Q3) ended September 30, 2026. Q3 2026 Highlights and Recent Events CyPath® Lung test unit sales increased 100% through Q3 compared to the first nine months of 2025. In July 2026, the Company surpassed the total number of CyPath Lung test reports delivered to physicians during 2025. The number of ordering physicians increased by 89% in the third qua…
Open exhibit ↗